SynthesisAbdominal radiology (New York)2026
Exploring radiological characteristics in beta-catenin-mutated hepatocellular adenoma: a systematic review and meta-analysis.
Synthesis in Abdominal radiology (New York), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- A case of β-catenin-activated hepatocellular adenoma with concurrent hepatocellular carcinoma.Abdominal radiology (New York) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular adenomas are rare benign liver tumors primarily affecting young women, particularly those using oral contraceptives. This systematic review and meta-analysis aimed to evaluate the radiologic features of beta-catenin mutated HCAs with a focus on enhancing diagnostic accuracy and informing management strategies. A comprehensive search of databases yielded 328 articles, with 13 meeting inclusion criteria. The analysis included 94 B-HCAs, revealing a mean size of 6.46 cm and a notable prevalence of necrosis (32.65%). Imaging characteristics demonstrated that T1-weighted MRI showed isointensity in 47% and hypointensity in 36% of lesions, while T2-weighted MRI indicated iso-mild hyperintensity in 60% and hyperintensity in 38%. In the arterial phase, 87% of lesions exhibited hyperenhancement. The presence of a central scar was noted in 47.05% of cases, while the atoll sign and intralesional hemorrhage were less common. The study found a significant tendency for malignant transformation, with 47.72% of B-HCAs evolving into malignant lesions. The findings suggest that B-HCAs may present features similar to focal nodular hyperplasia, complicating diagnosis. Given the high risk of malignancy, management strategies for B-HCAs should align with those for hepatocellular carcinoma. This review underscores the importance of comprehensive MRI evaluation and clinical context in diagnosing B-HCAs, advocating for cautious interpretation of imaging findings to guide potential biopsy decisions.
Indexed as
Identifiers
40719924What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.